SCHEMBL288476

SCHEMBL288476

C[CH]c1nc2ccccc2s1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.57
RAB9A P51151 7/20 0.57
MEN1 O00255 6/20 0.57
KMT2A Q03164 6/20 0.57
TDP1 Q9NUW8 3/20 0.57
SMN1; SMN2 Q16637 3/20 0.54
APP P05067 1/20 0.54
INSR P06213 1/20 0.54
NCOA1 Q15788 1/20 0.54
NPC1 O15118 5/20 0.53
L3MBTL1 Q9Y468 3/20 0.53
CASP3 P42574 1/20 0.53
SENP7 Q9BQF6 1/20 0.53
ALDH1A1 P00352 4/20 0.50
CYP1A2 P05177 3/20 0.50
CYP2D6 P10635 3/20 0.50
CYP3A4 P08684 2/20 0.50
CYP2C19 P33261 2/20 0.50
ADRA2A P08913 1/20 0.50
FBP1 P09467 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16118383 0.86 MAPT (0.61) MAPTRAB9AMEN1KMT2ATDP1
SCHEMBL13596251 0.86 MAPT (0.61) MAPTRAB9AMEN1KMT2ATDP1
SCHEMBL14432528 0.86 MAPT (0.61) MAPTRAB9AMEN1KMT2ATDP1
SCHEMBL27644430 0.83 MAPT (0.50) MAPTRAB9AMEN1KMT2ATDP1
SCHEMBL8904881 0.82 MAPT (0.54) MAPTRAB9AMEN1KMT2ATDP1
SCHEMBL29881859 0.81 MAPT (0.56) MAPTRAB9AMEN1KMT2ATDP1
SCHEMBL28820669 0.81 MAPT (0.56) MAPTRAB9AMEN1KMT2ATDP1
SCHEMBL719081 0.81 MAPT (0.56) MAPTRAB9AMEN1KMT2ATDP1
SCHEMBL3096386 0.81 MAPT (0.51) MAPTRAB9AMEN1KMT2ATDP1
SCHEMBL19844258 0.81 RAB9A (0.51) MAPTRAB9AMEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5504081-A ADMINISTERING NICOTINERGIC ACETYLCHOLINE RECEPTOR ANTAGONISTS AND AGONISTS BAYER AKTIENGESELLSCHAFT (DE) 1996-04-02 US claimed
CN-116615423-A Novel peptidomimetic compounds and design 株式会社大分大学先端医学研究所 2023-08-18 CN disclosed
US-11661410-B2 Tricyclic compounds as histone methyltransferase inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-05-30 US disclosed
US-11584734-B2 Tricyclic compounds as histone methyltransferase inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-02-21 US disclosed
US-20230002351-A1 TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2023-01-05 US disclosed
US-20200361896-A1 TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2020-11-19 US disclosed
CN-111372927-A Tricyclic compounds as histone methyltransferase inhibitors 全球血液疗法股份有限公司 2020-07-03 CN disclosed
EP-3668863-A1 TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS Global Blood Therapeutics, Inc. (US) 2020-06-24 EP disclosed
WO-2019036384-A1 TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2019-02-21 WO disclosed
WO-2019036377-A1 TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2019-02-21 WO disclosed
US-20100240671-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS INCYTE CORPORATION (US) 2010-09-23 US disclosed
US-7745630-B2 Triazolyl piperidine arginine vasopressin receptor modulators BRYANS JUSTIN STEPHEN 2010-06-29 US disclosed
US-20050154024-A1 Compounds useful in therapy PFIZER INC 2005-07-14 US disclosed
WO-2005025554-A2 DIPEPTIDYL PEPTIDASE IV INHIBITOR JAPAN TOBACCO INC. (JP) 2005-03-24 WO disclosed
CN-1193020-C Process for preparing amic acid esters IHARA CHEMICAL IND CO (JP) 2005-03-16 CN disclosed
US-6576765-B2 Process for preparing amic acid esters IHARA CHEMICAL INDUSTRY CO., LTD. (JP) 2003-06-10 US disclosed
US-20030032667-A1 PROCESS FOR PREPARING AMIC ACID ESTERS IHARA CHEMICAL INDUSTRY CO., LTD. (JP) 2003-02-13 US disclosed
CN-1366523-A Process for preparing amic acid esters IHARA CHEMICAL IND CO (JP) 2002-08-28 CN disclosed
EP-1182199-A1 PROCESS FOR PREPARING AMIC ACID ESTERS IHARA CHEMICAL INDUSTRY Co., Ltd. (JP) 2002-02-27 EP disclosed
CN-1121711-A 3-(hetero)aryl carboxylic acid derivatives, methods of preparing them and intermediates used in their preparation BASF AG (DE) 1996-05-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002351-A1 TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS EHMT1, EHMT2, BMI1 MAPT 2437/4885RAB9A 1696/4885MEN1 796/4885
US-11661410-B2 Tricyclic compounds as histone methyltransferase inhibitors EHMT1, EHMT2, BMI1 MAPT 2437/4885RAB9A 1696/4885MEN1 796/4885
US-20100240671-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS HRH4, HRH2, HRH1 MAPT 2968/4885RAB9A 1809/4885MEN1 3268/4885
US-11584734-B2 Tricyclic compounds as histone methyltransferase inhibitors EHMT1, EHMT2, BMI1 MAPT 2954/4885RAB9A 1619/4885MEN1 616/4885
US-20050154024-A1 Compounds useful in therapy PTGER4, PTGER3, ALOX5 MAPT 4829/4885RAB9A 3475/4885MEN1 2639/4885
US-20030032667-A1 PROCESS FOR PREPARING AMIC ACID ESTERS MCCC2, EMC1, GANC MAPT 4719/4885RAB9A 774/4885MEN1 1208/4885
US-20200361896-A1 TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS EHMT1, EHMT2, BMI1 MAPT 2954/4885RAB9A 1619/4885MEN1 616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.